Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Michael E. Carney is active.

Publication


Featured researches published by Michael E. Carney.


Nature Genetics | 2009

A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2

Honglin Song; Susan J. Ramus; Jonathan Tyrer; Kelly L. Bolton; Aleksandra Gentry-Maharaj; Eva Wozniak; Hoda Anton-Culver; Jenny Chang-Claude; Daniel W. Cramer; Richard A. DiCioccio; Thilo Dörk; Ellen L. Goode; Marc T. Goodman; Joellen M. Schildkraut; Thomas A. Sellers; Laura Baglietto; Matthias W. Beckmann; Jonathan Beesley; Jan Blaakær; Michael E. Carney; Stephen J. Chanock; Zhihua Chen; Julie M. Cunningham; Ed Dicks; Jennifer A. Doherty; Matthias Dürst; Arif B. Ekici; David Fenstermacher; Brooke L. Fridley; Graham G. Giles

Epithelial ovarian cancer has a major heritable component, but the known susceptibility genes explain less than half the excess familial risk. We performed a genome-wide association study (GWAS) to identify common ovarian cancer susceptibility alleles. We evaluated 507,094 SNPs genotyped in 1,817 cases and 2,353 controls from the UK and ∼2 million imputed SNPs. We genotyped the 22,790 top ranked SNPs in 4,274 cases and 4,809 controls of European ancestry from Europe, USA and Australia. We identified 12 SNPs at 9p22 associated with disease risk (P < 10−8). The most significant SNP (rs3814113; P = 2.5 × 10−17) was genotyped in a further 2,670 ovarian cancer cases and 4,668 controls, confirming its association (combined data odds ratio (OR) = 0.82, 95% confidence interval (CI) 0.79–0.86, Ptrend = 5.1 × 10−19). The association differs by histological subtype, being strongest for serous ovarian cancers (OR 0.77, 95% CI 0.73–0.81, Ptrend = 4.1 × 10−21).


Lancet Oncology | 2013

Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study

Weiva Sieh; Martin Köbel; Teri A. Longacre; David Bowtell; Anna deFazio; Marc T. Goodman; Estrid Høgdall; Suha Deen; Nicolas Wentzensen; Kirsten B. Moysich; James D. Brenton; Blaise Clarke; Usha Menon; C. Blake Gilks; Andre Kim; Jason Madore; Sian Fereday; Joshy George; Laura Galletta; Galina Lurie; Lynne R. Wilkens; Michael E. Carney; Pamela J. Thompson; Rayna K. Matsuno; Susanne K. Kjaer; Allan Jensen; Claus Høgdall; Kimberly R. Kalli; Brooke L. Fridley; Gary L. Keeney

BACKGROUND Few biomarkers of ovarian cancer prognosis have been established, partly because subtype-specific associations might be obscured in studies combining all histopathological subtypes. We examined whether tumour expression of the progesterone receptor (PR) and oestrogen receptor (ER) was associated with subtype-specific survival. METHODS 12 studies participating in the Ovarian Tumor Tissue Analysis consortium contributed tissue microarray sections and clinical data to our study. Participants included in our analysis had been diagnosed with invasive serous, mucinous, endometrioid, or clear-cell carcinomas of the ovary. For a patient to be eligible, tissue microarrays, clinical follow-up data, age at diagnosis, and tumour grade and stage had to be available. Clinical data were obtained from medical records, cancer registries, death certificates, pathology reports, and review of histological slides. PR and ER statuses were assessed by central immunohistochemistry analysis done by masked pathologists. PR and ER staining was defined as negative (<1% tumour cell nuclei), weak (1 to <50%), or strong (≥50%). Associations with disease-specific survival were assessed. FINDINGS 2933 women with invasive epithelial ovarian cancer were included: 1742 with high-grade serous carcinoma, 110 with low-grade serous carcinoma, 207 with mucinous carcinoma, 484 with endometrioid carcinoma, and 390 with clear-cell carcinoma. PR expression was associated with improved disease-specific survival in endometrioid carcinoma (log-rank p<0·0001) and high-grade serous carcinoma (log-rank p=0·0006), and ER expression was associated with improved disease-specific survival in endometrioid carcinoma (log-rank p<0·0001). We recorded no significant associations for mucinous, clear-cell, or low-grade serous carcinoma. Positive hormone-receptor expression (weak or strong staining for PR or ER, or both) was associated with significantly improved disease-specific survival in endometrioid carcinoma compared with negative hormone-receptor expression, independent of study site, age, stage, and grade (hazard ratio 0·33, 95% CI 0·21-0·51; p<0·0001). Strong PR expression was independently associated with improved disease-specific survival in high-grade serous carcinoma (0·71, 0·55-0·91; p=0·0080), but weak PR expression was not (1·02, 0·89-1·18; p=0·74). INTERPRETATION PR and ER are prognostic biomarkers for endometrioid and high-grade serous ovarian cancers. Clinical trials, stratified by subtype and biomarker status, are needed to establish whether hormone-receptor status predicts response to endocrine treatment, and whether it could guide personalised treatment for ovarian cancer. FUNDING Carraresi Foundation and others.


Endocrine-related Cancer | 2013

Obesity and risk of ovarian cancer subtypes: evidence from the Ovarian Cancer Association Consortium

Catherine M. Olsen; Christina M. Nagle; David C. Whiteman; Roberta B. Ness; Celeste Leigh Pearce; Malcolm C. Pike; Mary Anne Rossing; Kathryn L. Terry; Anna H. Wu; Harvey A. Risch; Herbert Yu; Jennifer A. Doherty; Jenny Chang-Claude; Rebecca Hein; Stefan Nickels; Shan Wang-Gohrke; Marc T. Goodman; Michael E. Carney; Rayna K. Matsuno; Galina Lurie; Kirsten B. Moysich; Susanne K. Kjaer; Allan Jensen; Estrid Høgdall; Ellen L. Goode; Brooke L. Fridley; Robert A. Vierkant; Melissa C. Larson; Joellen M. Schildkraut; Cathrine Hoyo

Whilst previous studies have reported that higher BMI increases a womans risk of developing ovarian cancer, associations for the different histological subtypes have not been well defined. As the prevalence of obesity has increased dramatically, and classification of ovarian histology has improved in the last decade, we sought to examine the association in a pooled analysis of recent studies participating in the Ovarian Cancer Association Consortium. We evaluated the association between BMI (recent, maximum and in young adulthood) and ovarian cancer risk using original data from 15 case-control studies (13 548 cases and 17 913 controls). We combined study-specific adjusted odds ratios (ORs) using a random-effects model. We further examined the associations by histological subtype, menopausal status and post-menopausal hormone use. High BMI (all time-points) was associated with increased risk. This was most pronounced for borderline serous (recent BMI: pooled OR=1.24 per 5 kg/m(2); 95% CI 1.18-1.30), invasive endometrioid (1.17; 1.11-1.23) and invasive mucinous (1.19; 1.06-1.32) tumours. There was no association with serous invasive cancer overall (0.98; 0.94-1.02), but increased risks for low-grade serous invasive tumours (1.13, 1.03-1.25) and in pre-menopausal women (1.11; 1.04-1.18). Among post-menopausal women, the associations did not differ between hormone replacement therapy users and non-users. Whilst obesity appears to increase risk of the less common histological subtypes of ovarian cancer, it does not increase risk of high-grade invasive serous cancers, and reducing BMI is therefore unlikely to prevent the majority of ovarian cancer deaths. Other modifiable factors must be identified to control this disease.


Biochemical Pharmacology | 1997

Human ovarian cancer of the surface epithelium

Andrew Berchuck; Michael E. Carney

Epidemiologic studies have shown that the risk of cancer in the ovarian surface epithelium is decreased by factors that suppress ovulation, whereas uninterrupted ovulation has been associated with increased risk. This suggests that ovulation may play a critical role in ovarian carcinogenesis. More recently, molecular studies have demonstrated alterations in specific oncogenes and tumor suppressor genes in ovarian cancers. Overexpression of the HER-2/neu oncogene occurs in approximately 30% of ovarian cancers and correlates with poor survival. Although mutation of the K-ras oncogene has been found in some mucinous ovarian cancers, mutations in this gene appear to be more common in borderline ovarian tumors. Amplification of c-myc occurs in approximately 30% of ovarian cancers and is more frequently seen in serous cancers. Mutation of the p53 tumor suppressor gene, with resultant overexpression of mutant p53 protein, occurs in 50% of stage III/IV and 15% of stage I/II ovarian cancers. Most p53 mutations in ovarian cancers are transitions, which suggests that they arise spontaneously rather than due to exogenous carcinogens. In contrast to the acquired genetic alterations described above that are a feature of sporadic ovarian cancers, 5-10% of ovarian cancers probably arise due to inherited genetic defects. Recently, the BRCA1 tumor suppressor gene has heen identified and shown to be responsible for most cases of hereditary ovarian cancer. Further studies are needed to augment our understanding of the molecular pathogenesis of ovarian cancer.


Cancer Research | 2007

Tagging Single Nucleotide Polymorphisms in Cell Cycle Control Genes and Susceptibility to Invasive Epithelial Ovarian Cancer

Simon A. Gayther; Honglin Song; Susan J. Ramus; Sk Kjaer; Alice S. Whittemore; Lydia Quaye; Jonathan Tyrer; Danielle Shadforth; Estrid Høgdall; Claus Høgdall; Jan Blaeker; Richard A. DiCioccio; Valerie McGuire; Penelope M. Webb; Jonathan Beesley; Adèle C. Green; David C. Whiteman; Marc T. Goodman; Galina Lurie; Michael E. Carney; Francesmary Modugno; Roberta B. Ness; Robert P. Edwards; Kirsten B. Moysich; Ellen L. Goode; Fergus J. Couch; Julie M. Cunningham; Thomas A. Sellers; Anna H. Wu; Malcolm C. Pike

High-risk susceptibility genes explain <40% of the excess risk of familial ovarian cancer. Therefore, other ovarian cancer susceptibility genes are likely to exist. We have used a single nucleotide polymorphism (SNP)-tagging approach to evaluate common variants in 13 genes involved in cell cycle control-CCND1, CCND2, CCND3, CCNE1, CDK2, CDK4, CDK6, CDKN1A, CDKN1B, CDKN2A, CDKN2B, CDKN2C, and CDKN2D-and risk of invasive epithelial ovarian cancer. We used a two-stage, multicenter, case-control study. In stage 1, 88 SNPs that tag common variation in these genes were genotyped in three studies from the United Kingdom, United States, and Denmark ( approximately 1,500 cases and 2,500 controls). Genotype frequencies in cases and controls were compared using logistic regression. In stage 2, eight other studies from Australia, Poland, and the United States ( approximately 2,000 cases and approximately 3,200 controls) were genotyped for the five most significant SNPs from stage 1. No SNP was significant in the stage 2 data alone. Using the combined stages 1 and 2 data set, CDKN2A rs3731257 and CDKN1B rs2066827 were associated with disease risk (unadjusted P trend = 0.008 and 0.036, respectively), but these were not significant after adjusting for multiple testing. Carrying the minor allele of these SNPs was found to be associated with reduced risk [OR, 0.91 (0.85-0.98) for rs3731257; and OR, 0.93 (0.87-0.995) for rs2066827]. In conclusion, we have found evidence that a single tagged SNP in both the CDKN2A and CDKN1B genes may be associated with reduced ovarian cancer risk. This study highlights the need for multicenter collaborations for genetic association studies.


International Journal of Cancer | 2008

Consortium analysis of 7 candidate SNPs for ovarian cancer.

Susan J. Ramus; Robert A. Vierkant; Sharon E. Johnatty; Malcolm C. Pike; David Van Den Berg; Anna H. Wu; Celeste Leigh Pearce; Usha Menon; Aleksandra Gentry-Maharaj; Simon A. Gayther; Richard A. DiCioccio; Valerie McGuire; Alice S. Whittemore; Honglin Song; Douglas F. Easton; Paul Pharoah; Montserrat Garcia-Closas; Stephen J. Chanock; Jolanta Lissowska; Louise A. Brinton; Kathryn L. Terry; Daniel W. Cramer; Shelley S. Tworoger; Susan E. Hankinson; Andrew Berchuck; Patricia G. Moorman; Joellen M. Schildkraut; Julie M. Cunningham; Mark Liebow; Susanne K. Kjaer

The Ovarian Cancer Association Consortium selected 7 candidate single nucleotide polymorphisms (SNPs), for which there is evidence from previous studies of an association with variation in ovarian cancer or breast cancer risks. The SNPs selected for analysis were F31I (rs2273535) in AURKA, N372H (rs144848) in BRCA2, rs2854344 in intron 17 of RB1, rs2811712 5′ flanking CDKN2A, rs523349 in the 3′ UTR of SRD5A2, D302H (rs1045485) in CASP8 and L10P (rs1982073) in TGFB1. Fourteen studies genotyped 4,624 invasive epithelial ovarian cancer cases and 8,113 controls of white non‐Hispanic origin. A marginally significant association was found for RB1 when all studies were included [ordinal odds ratio (OR) 0.88 (95% confidence interval (CI) 0.79–1.00) p = 0.041 and dominant OR 0.87 (95% CI 0.76–0.98) p = 0.025]; when the studies that originally suggested an association were excluded, the result was suggestive although no longer statistically significant (ordinal OR 0.92, 95% CI 0.79–1.06). This SNP has also been shown to have an association with decreased risk in breast cancer. There was a suggestion of an association for AURKA, when one study that caused significant study heterogeneity was excluded [ordinal OR 1.10 (95% CI 1.01–1.20) p = 0.027; dominant OR 1.12 (95% CI 1.01–1.24) p = 0.03]. The other 5 SNPs in BRCA2, CDKN2A, SRD5A2, CASP8 and TGFB1 showed no association with ovarian cancer risk; given the large sample size, these results can also be considered to be informative. These null results for SNPs identified from relatively large initial studies shows the importance of replicating associations by a consortium approach.


Cancer Epidemiology, Biomarkers & Prevention | 2007

Vitamin D Receptor Gene Polymorphisms and Epithelial Ovarian Cancer Risk

Galina Lurie; Lynne R. Wilkens; Pamela J. Thompson; Michael E. Carney; Keith Y. Terada; Marc T. Goodman

Epidemiologic and laboratory studies support a role for the vitamin D endocrine system in ovarian carcinogenesis. The association of ovarian cancer risk with polymorphisms in the vitamin D receptor (VDR) gene, including rs10735810 (FokI), rs11568820 (Cdx-2), rs1544410 (BsmI), rs7975232 (ApaI), rs731236 (TaqI), and BsmI-ApaI-TaqI combined genotypes, was examined among 313 women with epithelial ovarian carcinoma and 574 controls. Odds ratios (OR) and 95% confidence intervals (95% CI) were estimated using unconditional logistic regression. The associations of VDR polymorphisms with risk were generally inconsistent across ethnic groups. Among Caucasian women (72 cases, 148 controls), heterozygous and homozygous ApaI A allele carriers were at increased ovarian carcinoma risk compared with homozygous carriers of the ApaI a allele (OR 2.8, 95% CI 1.2-7.0 and OR 3.4, 95% CI 1.3-9.1; Ptrend = 0.02). Caucasian heterozygous carriers of FokI f allele were also at increased risk of ovarian carcinoma compared with homozygous carriers of the common allele (OR 2.5, 95% CI 1.3-4.8; Ptrend = 0.04). Among Japanese women (94 cases, 173 controls), ovarian cancer risk was significantly decreased (OR 0.5, 95% CI 0.3-0.9) among Cdx-2 A allele heterozygotes compared with homozygote G allele carriers (Ptrend = 0.03). Compared with the bbaaTT BsmI-ApaI-TaqI genotype, bbaATT and BBAAtt genotypes were associated with increased ovarian cancer risk in Caucasian women (OR 4.2, 95% CI 1.3-13.1 and OR 5.2, 95% CI 1.6-17.5), but not in Japanese women (OR 1.1, 95% CI 0.6-1.9 and OR 2.3, 95% CI:0.4-12.3). This investigation provides some evidence that polymorphisms in the VDR gene might influence ovarian cancer susceptibility. (Cancer Epidemiol Biomarkers Prev 2007;16(12):2566–71)


Cancer Research | 2009

Single Nucleotide Polymorphisms in the TP53 Region and Susceptibility to Invasive Epithelial Ovarian Cancer

Joellen M. Schildkraut; Ellen L. Goode; Merlise A. Clyde; Edwin S. Iversen; Patricia G. Moorman; Andrew Berchuck; Jeffrey R. Marks; Jolanta Lissowska; Louise A. Brinton; Beata Peplonska; Julie M. Cunningham; Robert A. Vierkant; David N. Rider; Georgia Chenevix-Trench; Penelope M. Webb; Jonathan Beesley; Xiaoqing Chen; Catherine M. Phelan; Rebecca Sutphen; Thomas A. Sellers; Leigh Pearce; Anna H. Wu; David Van Den Berg; David V. Conti; Christopher K. Elund; Rebecca Anderson; Marc T. Goodman; Galina Lurie; Michael E. Carney; Pamela J. Thompson

The p53 protein is critical for multiple cellular functions including cell growth and DNA repair. We assessed whether polymorphisms in the region encoding TP53 were associated with risk of invasive ovarian cancer. The study population includes a total of 5,206 invasive ovarian cancer cases (2,829 of which were serous) and 8,790 controls from 13 case-control or nested case-control studies participating in the Ovarian Cancer Association Consortium (OCAC). Three of the studies performed independent discovery investigations involving genotyping of up to 23 single nucleotide polymorphisms (SNP) in the TP53 region. Significant findings from this discovery phase were followed up for replication in the other OCAC studies. Mixed effects logistic regression was used to generate posterior median per allele odds ratios (OR), 95% probability intervals (PI), and Bayes factors (BF) for genotype associations. Five SNPs showed significant associations with risk in one or more of the discovery investigations and were followed up by OCAC. Mixed effects analysis confirmed associations with serous invasive cancers for two correlated (r(2) = 0.62) SNPs: rs2287498 (median per allele OR, 1.30; 95% PI, 1.07-1.57) and rs12951053 (median per allele OR, 1.19; 95% PI, 1.01-1.38). Analyses of other histologic subtypes suggested similar associations with endometrioid but not with mucinous or clear cell cancers. This large study provides statistical evidence for a small increase in risk of ovarian cancer associated with common variants in the TP53 region.


Cancer | 2003

Stage at diagnosis of ovarian cancer in the United States, 1992-1997.

Marc T. Goodman; Catherine N. Correa; Ko-Hui Tung; Steven D. Roffers; Xiao-Cheng Wu; John L. Young; Lynne R. Wilkens; Michael E. Carney; Holly L. Howe

Received March 18, 2002; revision received September 25, 2002; accepted January 15, 2003. In the early stages of epithelial ovarian cancer, symptoms typically are mild or nonspecific (e.g., abdominal discomfort, bloating, or back pain) and therefore are difficult to distinguish from symptoms of other common illnesses. Approximately 95% of women who are diagnosed and treated with localized disease that has not spread beyond the ovary survive for 5 years, but only about 25% of women with ovarian cancer are diagnosed at this early stage. Five-year survival decreases to approximately 28% when distant spread has occurred, and 75% of women with surgically staged ovarian cancer are diagnosed with metastatic disease that has this poor prognosis. This purpose of the current article is to describe the stage at diagnosis of ovarian cancer among white, black, Asian and Pacific Islander, American Indian, and Hispanic women in the United States from 1992 through 1997 using a comparable staging system. Cancer stage describes the extent of the malignant process— higher values denote greater disease severity. Although all staging systems are inherently imperfect attempts to categorize complex biologic processes, they are nonetheless necessary for statistical analysis of cancer cases with similar prognostic characteristics; for instance, disease stage at diagnosis influences treatment options. In the United States, the systems most often used for the clinical staging of ovarian cancers are the FIGO (International Federation of Gynecology and Obstetrics) system and the American Joint Committee on Cancer TNM system. Not all population-based cancer registries collect data regarding each of the specific components of the TNM or FIGO system. However, all registries do use a summary stage variable, developed by the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) Program, to group cases into one of five categories: in situ, localized, regional, distant, and unknown. Although the FIGO and SEER Summary Stage systems are not directly interconvertible, what follows is a general translation. In situ cancer is confined to the ovary without stromal invasion or penetration of the basement membrane. Diagnosis of an in situ cancer can only be made microscopically. Localized ovarian cancer has infiltrated the epithelium, but invasion has not spread beyond the ovary (FIGO Stages IA and IB). Regional cancer has spread beyond the ovary by direct extension to adjacent tissue and/or regional lymph node involvement (FIGO Stages IC, IIA–C). Distant or metastatic ovarian cancer includes tumor cells that have broken away from the primary tumor and have begun to grow in a new, remote location beyond the pelvis (FIGO Stages IIIA–C, IV). Some registries collect disease stage information directly, whereas others derive the categories by aggregating specific descrip2648


Cancer Epidemiology, Biomarkers & Prevention | 2010

ESR1/SYNE1 polymorphism and invasive epithelial ovarian cancer risk: an Ovarian Cancer Association Consortium study.

Jennifer A. Doherty; Mary Anne Rossing; Kara L. Cushing-Haugen; Chu Chen; David Van Den Berg; Anna H. Wu; Malcolm C. Pike; Roberta B. Ness; Kirsten B. Moysich; Georgia Chenevix-Trench; Jonathan Beesley; Penelope M. Webb; Jenny Chang-Claude; Shan Wang-Gohrke; Marc T. Goodman; Galina Lurie; Pamela J. Thompson; Michael E. Carney; Estrid Høgdall; Susanne K. Kjaer; Claus Høgdall; Ellen L. Goode; Julie M. Cunningham; Brooke L. Fridley; Robert A. Vierkant; Andrew Berchuck; Patricia G. Moorman; Joellen M. Schildkraut; Rachel T. Palmieri; Daniel W. Cramer

We genotyped 13 single nucleotide polymorphisms (SNPs) in the estrogen receptor alpha gene (ESR1) region in three population-based case-control studies of epithelial ovarian cancer conducted in the United States, comprising a total of 1,128 and 1,866 non-Hispanic white invasive cases and controls, respectively. A SNP 19 kb downstream of ESR1 (rs2295190, G-to-T change) was associated with invasive ovarian cancer risk, with a per-T-allele odds ratio (OR) of 1.24 [95% confidence interval (CI), 1.06-1.44, P = 0.006]. rs2295190 is a nonsynonymous coding SNP in a neighboring gene called spectrin repeat containing, nuclear envelope 1 (SYNE1), which is involved in nuclear organization and structural integrity, function of the Golgi apparatus, and cytokinesis. An isoform encoded by SYNE1 has been reported to be downregulated in ovarian and other cancers. rs2295190 was genotyped in an additional 12 studies through the Ovarian Cancer Association Consortium, with 5,279 invasive epithelial cases and 7,450 controls. The per-T-allele OR for this 12-study set was 1.09 (95% CI, 1.02-1.17; P = 0.017). Results for the serous subtype in the 15 combined studies were similar to those overall (n = 3,545; OR, 1.09; 95% CI, 1.01-1.18; P = 0.025), and our findings were strongest for the mucinous subtype (n = 447; OR, 1.32; 95% CI, 1.11-1.58; P = 0.002). No association was observed for the endometrioid subtype. In an additional analysis of 1,459 borderline ovarian cancer cases and 7,370 controls, rs2295190 was not associated with risk. These data provide suggestive evidence that the rs2295190 T allele, or another allele in linkage disequilibrium with it, may be associated with increased risk of invasive ovarian cancer. Cancer Epidemiol Biomarkers Prev; 19(1); 244–50

Collaboration


Dive into the Michael E. Carney's collaboration.

Top Co-Authors

Avatar

Marc T. Goodman

University of Southern California

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Roberta B. Ness

University of Texas at Austin

View shared research outputs
Top Co-Authors

Avatar

Mary Anne Rossing

University of Texas Health Science Center at Houston

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge